Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of
immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites …

目的: 探讨1q21 扩增(简称1q) 对于初治多发性骨髓瘤(NDMM) 预后的影响. 方法:
回顾性分析2014 年1 月—2020 年8 月在徐州医科大学附属医院行FISH 检测并规范治疗的171 …

Multiple myeloma (MM) is an incurable plasma cell malignancy with a heterogeneous
genetic background. Each MM subtype may have its own therapeutic vulnerabilities, and …

Long‐term disease control in multiple myeloma (MM) is typically an unmet medical need,
and most patients experience multiple relapses. Fluorescence in situ hybridization (FISH) is …

Introduction The gain/amplification (amp) of 1q21 is one of the most common high‐risk
chromosome abnormality (HRCA) in multiple myeloma (MM). The prognostic value of 1q21+ …

High-risk cytogenetic abnormalities (HRCAs) are the most critical factor affecting prognosis
in multiple myeloma (MM). However, the clinical significance of HRCAs in routine practice …

Multiple myeloma (MM) is a disorder of the monoclonal plasma cells and is the second most
common hematologic malignancy. MM initiation and progression are dependent upon …

The treatment of patients with relapsed and refractory multiple myeloma has become
increasingly complex due to the rising number of available therapies. Patients are also …

Multiple myeloma (MM) is a clonal plasma cell malignancy with a heterogeneous disease
course. Insights into the genetics of the disease have identified certain high-risk cytogenetic …

Multiple myeloma (MM) is a biologically heterogeneous malignancy defined by the
proliferation of monoclonal plasma cells. Despite the tremendous advancement in MM …